Efficacy data in unresectable or metastatic hepatocellular carcinoma (HCC)
Select an option to learn more about OPDIVO® + YERVOY®
NOW APPROVED
1L Unresectable or Metastatic HCC
OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
2L Unresectable or Metastatic HCC
OPDIVO, in combination with YERVOY, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
1L=first-line; 2L=second-line.